GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Stats] relative risk reduction sells papers, absolute risk reduction makes decisions — 58 comments in the full submission. View in context.
731
c/trialwatch·submitted 4 days ago by u/britta_boateng

[Stats] relative risk reduction sells papers, absolute risk reduction makes decisions

Statsbranch of 5 comments

Genuinely asking, not being difficult. Everyone in c/compounding repeats that hazard ratio is important. I believe it, but I have never seen anyone show why, and when I search I get 6 threads of people agreeing with each other. Is there a paper? Is there a measurement? Or is this one of those things that is true…

Read the full submission and all 58 comments →

This branch

5 comments, started 3 days ago
u/rania_salinas7 points·3 days ago

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

replysharereportpermalink
u/laila_almeida6 points·3 days ago·edited

the discontinuation arms are the interesting part, not the endpoint endpoints

replysharereportpermalink
u/cloudy_vial_carol5 points·3 days ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/britta_boatengOP3 points·3 days ago

phase 2 is not phase 3, smaller n and shorter trial

Yes, exactly this, and it is the bit that took me 5 weeks to accept.

replysharereportpermalink
u/cesar_ivaturi2 points·3 days ago

SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →